Orbus Therapeutics Secures $32.5 Million Series A Financing to Advance Late-Stage Brain Cancer Drug by longitudeadmin | Aug 19, 2015 | Portfolio News
Esperion Therapeutics Provides Update on the ETC-1002 Development Program Following End-of-Phase 2 Meeting With FDA by longitudeadmin | Aug 17, 2015 | Portfolio News
Collegium Reports Second Quarter Financial Results and Provides Corporate Update by longitudeadmin | Aug 12, 2015 | Portfolio News
Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by longitudeadmin | Aug 11, 2015 | Portfolio News
